# A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC

> **NCT04004234** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Biliary Tract Cancer (BTC)

## Interventions

- **DRUG:** Manganese Chloride
- **DRUG:** nab-paclitaxel
- **DRUG:** Gemcitabine
- **DRUG:** anti-PD-1 antibody

## Key facts

- **NCT ID:** NCT04004234
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-01
- **Primary completion:** 2020-08-31
- **Final completion:** 2021-08-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2019-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04004234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04004234, "A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04004234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*